Thymosin Alpha-1 (Thymalfasin): What the Research Actually Shows

What is thymosin alpha-1 (thymalfasin)?

Thymosin alpha-1 is a small peptide — a chain of 28 amino acids with an acetylated N-terminal end — that the body produces as a fragment of a larger protein called prothymosin alpha. It was first isolated and characterized in the 1970s by Allan Goldstein and colleagues from a thymic extract known as thymosin fraction 5, which is where the "thymosin" name comes from. Peptides in this size range are common signaling molecules rather than structural building blocks (PubMed 32965931).

The synthetic version used as a drug is called thymalfasin, and the best-known brand is Zadaxin, marketed by SciClone Pharmaceuticals. It has been sold internationally for more than two decades. A 2020 review in the World Journal of Virology traces this history and describes thymosin alpha-1 as one of the most extensively studied immune-modulating peptides in clinical use anywhere in the world (PubMed 33362999).

The distinction that matters most for readers in the United States: being a genuine, approved pharmaceutical in dozens of countries is not the same as being FDA-approved. Thymosin alpha-1 is both — an established medicine abroad and an unapproved compound at home — and that split runs through everything below.

How does thymosin alpha-1 work?

Thymosin alpha-1 does not kill viruses or bacteria directly. It works on the host immune system. Its central action is to nudge a suppressed, exhausted, or immature immune response back toward normal function, which is why it is classed as an immunomodulator rather than an antiviral or antibiotic.

Mechanistically, the peptide signals through pattern-recognition receptors on immune cells — notably Toll-like receptors such as TLR2 and TLR9 — on dendritic cells and monocytes. That signaling helps dendritic cells mature, promotes the development and activation of T cells, tilts the response toward a Th1 (antiviral) pattern, and supports natural killer cell activity. A 2016 review in Vitamins and Hormones lays out this immune-modulation profile in detail (PubMed 27450734), and a 2023 review focused specifically on viral disease describes how these effects translate into a broader antiviral posture (PubMed 37110771).

That mechanism explains the pattern of conditions it has been tested in. Chronic viral hepatitis, sepsis, and severe COVID-19 all share a feature: the immune system is either being outrun by the disease or has become dysfunctional in fighting it. A drug that restores immune competence, rather than one that targets a single pathogen, is a logical candidate across all three.

What is thymosin alpha-1 used for, and where is it approved?

In the countries where it is approved, thymosin alpha-1 has three main documented uses.

Chronic hepatitis B and C. This is the primary approved indication and the area with the deepest evidence base. A 2015 review in Expert Opinion on Biological Therapy summarizes the chronic hepatitis B data, where thymosin alpha-1 has been studied as monotherapy and, more effectively, in combination with antivirals or interferon, with endpoints such as viral load, ALT normalization, and hepatitis B e-antigen seroconversion (PubMed 25640173). Results for monotherapy have been modest and mixed; the combination story is stronger.

Immune adjunct in cancer care and vaccination. It has been used to support immune function during chemotherapy and to try to improve responses to vaccines in people whose immunity is blunted, such as older adults and dialysis patients.

Critical illness and infection. This is the newer and more heavily marketed frontier — sepsis and, since 2020, COVID-19 — covered in the next two sections.

Geographically, thymalfasin is approved and marketed in more than 30 countries, with a particularly long track record in China and across parts of Asia, Latin America, and southern Europe. The United States is a notable holdout: despite being developed partly by US researchers, it has never cleared the FDA.

Does thymosin alpha-1 work for sepsis?

Sepsis is where the immunomodulation idea is most compelling in principle. Severe sepsis is not simply an overwhelming infection; it often involves a phase of immune paralysis in which the body cannot mount an effective defense. A drug that restores T-cell function has an obvious rationale there.

The landmark study is the ETASS trial — "the efficacy of thymosin alpha 1 for severe sepsis" — a multicenter, single-blind, randomized controlled trial of 361 patients published in Critical Care in 2013. In the group given thymosin alpha-1, 28-day all-cause mortality was 26.0%, versus 35.0% in the control group. That is a 9 percentage-point reduction, but it did not reach statistical significance in the trial's primary analysis (PubMed 23327199). ETASS is best read as encouraging but underpowered — a promising signal rather than proof.

Meta-analyses that pool ETASS with other randomized trials have tended to land on the favorable side. A 2016 systematic review concluded that thymosin alpha-1 as immunomodulatory treatment was associated with reduced mortality in sepsis, while explicitly calling for larger, higher-quality trials (PubMed 27633969). A more recent 2025 systematic review and meta-analysis of randomized controlled trials, published in Frontiers in Cellular and Infection Microbiology, reached a similar conclusion — an association with lower short-term mortality — again tempered by concerns about study size and quality (PubMed 40969554).

The honest summary: multiple lines of evidence point the same direction, but the individual trials are mostly small, largely from single countries, and rated as moderate quality. That is enough to justify continued study; it is not enough to call the question settled.

Thymosin alpha-1 and COVID-19: what the studies found

When COVID-19 arrived, thymosin alpha-1 was already familiar to clinicians in China, and one feature of severe COVID made it an immediate candidate: profound lymphocytopenia, a collapse in circulating T cells that tracked with worse outcomes.

An early and widely cited retrospective study in Clinical Infectious Diseases reported that thymosin alpha-1 was associated with reduced mortality in severe COVID-19, and linked that benefit to restoration of lymphocyte counts and reversal of T-cell exhaustion (PubMed 32442287). It is an important mechanistic hint, but it was retrospective and observational, so it cannot establish cause and effect on its own.

Prospective work followed. A pilot randomized trial of thymalfasin in hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19, published in The Journal of Infectious Diseases in 2023, tested preliminary efficacy and safety against standard of care (PubMed 36056913). As a pilot, it was designed to inform larger trials rather than to deliver a definitive verdict.

Pulling the studies together, a 2023 systematic review, meta-analysis, and meta-regression in Inflammopharmacology examined thymosin alpha-1 in moderate to critical COVID-19 and reported an association with reduced mortality, while flagging heterogeneity between studies and the limits of the underlying evidence (PubMed 37845598). The pattern mirrors sepsis exactly: a consistent, plausible signal built on studies that individually fall short of the standard needed for a firm recommendation.

Is thymosin alpha-1 FDA approved or legal in the US?

Thymosin alpha-1 is not FDA-approved for any indication. There is no approved thymalfasin product on the US market, which is the single most important legal fact about it in an American context. It has held US orphan-drug designation for certain uses — a status that eases development but is explicitly not a marketing approval — and it never converted that into an approved drug.

Because there is no approved product, US access has historically flowed through compounding pharmacies, and that route has become contested. In 2023 the FDA placed thymosin alpha-1, along with a group of other popular peptides, on the interim Category 2 of its 503A bulk drug substances list — effectively a "do not compound pending further review" bucket — citing concerns about immunogenicity, impurities, and limited human safety data. The nomination supporting its inclusion was subsequently withdrawn, and the substance was removed from that Category 2 listing in 2024, leaving its long-term compounding status under continued review by the FDA and its advisory committee.

The practical takeaway is that the regulatory picture is genuinely fluid, not resolved, and it concerns compounding-pharmacy access rather than approval of a finished drug. Separately, vials of thymosin alpha-1 sold online and labeled "for research use only" are not approved medicines, are not made to pharmaceutical standards, and are not authorized for human use. Our overview of peptide legality and regulatory status explains how the approved-abroad, unapproved-at-home distinction plays out across this whole category.

Thymosin alpha-1 side effects reported in trials

On tolerability, thymosin alpha-1 has an unusually reassuring record for a drug that acts on the immune system, and this is one of the more consistent findings across the literature.

The most commonly reported adverse effect is a local injection-site reaction — pain, redness, or discomfort at the site, typically mild and short-lived. Beyond that, reviews describe occasional mild flu-like symptoms, low-grade fever, nausea, and rash. Crucially, and unlike the interferon and interleukin-2 therapies it is sometimes compared with, thymosin alpha-1 has not been associated with heavy systemic toxicity in most reports; the 2016 mechanism review notes it does not appear to induce the toxicities typical of those other biological response modifiers (PubMed 27450734). This clean profile is one reason it has been trialed so freely in critically ill patients.

Two caveats keep the picture honest. First, a favorable safety record in supervised clinical trials and approved-market use does not transfer to unregulated research-chemical vials of unknown purity, injected without oversight. Second, an immune-activating drug is not automatically appropriate in every immune state, which is exactly the kind of judgment that belongs to a treating clinician rather than a label. If you are keeping notes on any injectable, our summary of injection-site practice and rotation in the research literature is a useful companion.

Thymosin alpha-1 vs thymosin beta-4, TB-500 and other peptides

Thymosin alpha-1 is frequently confused with other "thymosin" and peptide-therapy products, and the differences are large. The useful comparison is not which is strongest but what each one actually is and how far it has traveled through formal evidence.

The single most common mix-up is with thymosin beta-4 and TB-500. They share the thymosin label only because both trace back to thymus extracts; beta-4 is a larger actin-binding molecule studied for repair, while alpha-1 is an immune signaler. The repair-peptide crowd — BPC-157, TB-500, and the copper peptide GHK-Cu — is a different conversation with a much thinner human evidence base than thymosin alpha-1 enjoys for hepatitis. And SS-31 (elamipretide) and MOTS-c sit in the mitochondrial and cellular space, unrelated to immune signaling. Thymosin alpha-1's genuine advantage over most peptides discussed in these communities is that it is a real, approved medicine somewhere, with randomized trials and a large post-marketing dataset behind it.

How long does thymosin alpha-1 take to work?

There is no single timeline, because the answer depends entirely on the condition and on the fact that this is an immune modulator, not a drug with a fast effect a person can feel.

In acute critical illness, the trials measured what matters on the relevant clock: immune markers such as lymphocyte counts over a period of days, and hard outcomes like 28-day mortality. The COVID-19 work, for instance, looked for restoration of T-cell numbers within the hospital stay (PubMed 32442287). In chronic hepatitis B, by contrast, published courses generally ran for about six months before endpoints like viral load and e-antigen seroconversion were judged (PubMed 25640173).

What thymosin alpha-1 does not do is produce a dramatic, same-day sensation. Its job is to shift immune-cell behavior, and that shows up in lab values and clinical outcomes rather than in how someone feels an hour after a dose. For anyone tracking a medication regimen where the real signal lives in numbers over weeks, a dated, consistent log beats memory — which is precisely the case for immune and infectious-disease treatments, where subjective impressions are easy to misread.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Thymosin alpha 1: A comprehensive review of the literature — PubMed 33362999
2. Immune Modulation with Thymosin Alpha 1 Treatment — PubMed 27450734
3. Thymosin alpha1 and Its Role in Viral Infectious Diseases — PubMed 37110771
4. Thymosin alpha-1 treatment in chronic hepatitis B — PubMed 25640173
5. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — PubMed 23327199
6. The efficacy of thymosin alpha-1 as immunomodulatory treatment for sepsis — PubMed 27633969
7. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials — PubMed 40969554
8. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells — PubMed 32442287
9. A Pilot Trial of Thymalfasin (Thymosin-alpha-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection — PubMed 36056913
10. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression — PubMed 37845598
11. Biochemistry, Peptide — PubMed 32965931

Keep reading